Bioprocessing & manufacturing · Viral vector cell lines
64x Bio
A Harvard spinout that engineers the cells which manufacture viral vectors, rather than the therapies those vectors carry. Two product lines are out, one patent is granted, and the gene therapy market it sells into has been contracting.
A cell asked to betray itself
Gene therapy runs on viral vectors, and viral vectors are grown inside human cells. That is the awkward part of the business. Cells spent a few hundred million years learning to shut virus production down, and a manufacturing run asks them to do the opposite, at volume, on a schedule.
George Church put the constraint in one clause when 64x Bio left stealth in November 2020. Cells have, he said, “if anything, evolved to minimize virus production”. Mutations that reverse that instinct are rare, and one useful cell line usually needs several working together. Screening candidates one at a time in plastic multiwell plates does not reach those numbers.
So 64x Bio stopped screening one at a time. It built a genetic barcoding method that ties a vector’s productivity back to the individual parent cell that made it. Millions of edited cells then compete inside the same reactor, and sequencing reads out afterwards which edits won. Alexis Rovner told GEN in 2025 that the team invented a way “to do pooled screens for AAV productivity”. Results feed a dataset the company calls CellMap, mined computationally to choose the next round of edits.
The bottleneck it sells into
At the Series A, 64x Bio said capacity “would need to increase by six orders of magnitude in many cases” for gene therapy to reach widespread disease. That figure is the company’s. The independent record supports the direction: Drug Discovery News reported in October 2025 that Luxturna, Zolgensma and Hemgenix carry list prices of roughly $850,000, $2.1 million and $3.5 million per dose. Cost of goods is part of why, and it is the part 64x Bio claims to move.
Founders
Rovner grew up wanting to be a musician. At Berkeley she found synthetic biology instead, then took a PhD at Yale in Farren Isaacs’ lab. She joined Church’s lab at Harvard Medical School and the Wyss Institute in early 2015, and co-founded the company out of that lab with Church, Pam Silver, Jeff Way and David Thompson.
She did not start from the technology. She started from a long survey of who needed it: “I had upwards of 800 additional touch points with industry experts and potential biotech partners to learn that viral vector manufacturing was one of the biggest problems in the biologics space.” The chief IP counsel at launch was Greg Sieczkiewicz, described in the 2020 release as the author of Moderna’s early patents. He is a named inventor on the patent the company now holds.
Stealth, a long quiet, then products
64x Bio went through Y Combinator in the Summer 2018 batch and was a top ten startup on Demo Day. It left stealth on November 16, 2020 with a $4.5 million seed led by First Round Capital, Fifty Years and Refactor Capital. On January 19, 2022 it announced a $55 million Series A led by Lifeforce Capital, whose general partner Sander Duncan joined the board. It had about ten employees and said it planned to reach fifty within the year.
Then the record goes almost silent for three years. The next dated item is April 29, 2025, when Charles River Laboratories named 64x Bio to the first cohort of its incubator program. AAV Apex Suite launched at the BIO convention on June 16, 2025, and LV Apex Suite for lentiviral vectors on June 29, 2026, with a CHO based biologics suite described as next.
The market moved while they built
The timing is uncomfortable. In September 2025 Biogen discontinued all gene therapy programs using AAV capsids, after Vertex, Pfizer and Takeda had made similar moves. Sarepta reported three patient deaths from acute liver failure, its trials went on hold and Elevidys shipments were suspended. Several firms that would have been this company’s largest customers have stepped back from the modality. The counter argument is that cost is exactly what broke, and that platform companies which fix it, in the words of one industry voice, “will define the next chapter of AAV”.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Granted US patent | US 12,241,062, “Mammalian cells and methods for engineering the same,” granted Mar 4, 2025 to 64-X, Inc. of San Francisco. Application 18/492,069, filed Oct 23, 2023. Rovner is first named inventor, with Gregory Sieczkiewicz and David Thompson among the others. | Public record |
| Earlier filing in the family | US 2024/0052341, same title and inventors, application 18/023,909, filed Sep 1, 2021. | Public record |
| Second technology family | US 2025/0197884, insect cells, filed Feb 28, 2023, sole listed inventor Rovner. Insect cells are the baculovirus route to AAV, a different system from HEK293. | Public record |
| AAV Apex Suite | Suspension adapted HEK293 lines for transient transfection, with processes said to deliver “titers exceeding E15 vg/L” and performance “independently confirmed by partners”. No partner has published that data under its own name. | Company-stated |
| LV Apex Suite | A suspension adapted transient cell line at “functional titers of 4E8 TU/mL”, announced Jun 29, 2026. Stable lines described as in development for both suites. | Company-stated |
| Named partner | Charles River Laboratories listed 64x Bio in its first incubator cohort, Apr 29, 2025. GEN reported the arrangement lets Charles River offer 64x Bio cell lines to other participants. | Independent |
| Unnamed partners | “Five leading global biopharma and CDMOs” in 2025, multiple in 2026. Charles River is the only one identified anywhere. | Company-stated |
| Papers and grants | No PubMed result for 64x Bio. No NIH RePORTER project and no NSF award under either name. All capital on record is equity. | Not found |
| SEC filings | No Form D and no EDGAR registrant under either name, despite $59.5 million in reported rounds. | Not found |
| Founding year | The company and GEN say 2017. Fierce Pharma and BioProcess International both reported 2020 at the Series A. The YC batch is Summer 2018. | Reports differ |
Read plainly: the intellectual property is real, dated and public, and one commercial relationship can be checked without taking the company’s word for it. Everything about how well the cell lines actually perform comes from 64x Bio. A titer figure no customer has put its own name to is a marketing number.
What to watch
- A named customer. Five collaborations were announced in 2025 and more in 2026, and only Charles River has surfaced.
- Titer data published by someone else, with a partner’s name on it.
- Stable producer cell lines. Both launches so far are transient, which still needs plasmid at every run.
- The CHO based biologics suite the company said in June 2026 was coming.
- A Series B, or a first Form D under 64-X, Inc. The last disclosed round closed in January 2022.
In their words
“The industry has poured billions of dollars into the expansion of vector manufacturing facilities in recent years. However, the problem is more fundamental than physical infrastructure. This is a genetics problem and the solutions are going to be in tailoring how a cell interacts with the viral components,”
George Church, PhD, co-founder, January 2022 financing release · Company release
“Viruses are a product of cellular gene expression, so there is no reason their production cannot be systematized in the same way antibody and enzyme production has been,”
Lex Rovner, PhD, CEO and co-founder, November 2020 launch release · Company release
“64x’s technology platform VectorSelect has the potential to reduce cost and increase manufacturing capacity by orders of magnitude.”
Sander Duncan, general partner, Lifeforce Capital, in BioProcess International, January 2022 · Independent
“The round only took a few months to close, which speaks to the industry need. We received our first term sheet in a week and half,”
Lex Rovner, to Business Insider, January 2022 · Independent
“Our goal is to really enable our partners to bring down COGS to a level where they can choose broader indications, which ultimately allows for these medicines to reach more patients.”
Lexi Rovner, to GEN at the BIO convention, June 2025 · Interview
“We’re also working with partners early to ensure they’re starting with the right cell line from day one.”
Alexis Rovner, Charles River incubator announcement, April 2025 · Partner release
“What’s shifting is the recognition that we need better control over the cost of goods, manufacturing consistency, and immunogenicity before AAV reaches its full commercial potential.”
Alan Griffith, VectorBuilder, to Drug Discovery News, October 2025 · Independent
Related companies
Sources
- Public recordUS Patent 12,241,062, assignee 64-X, Inc.
- Public recordUS Application 2025/0197884, insect cells
- Public recordEDGAR search, no registrant and no Form D
- Public recordNIH RePORTER search, no award
- Public recordPubMed search, no matching affiliation
- IndependentHarvard offshoot 64x Bio nets $55M in series A funding
- Independent64x Bio Raises $55M To Advance Gene Therapy Platform
- Independent64x Bio bags $55m to drive cell production tech
- IndependentThe 10-slide deck 64x Bio used to raise $55 million
- IndependentAt BIO, Companies Launch New Products for AAV Manufacturing
- IndependentIs AAV gene therapy at a turning point?
- InterviewLex Rovner Wants to Transform AAV Manufacturing
- InterviewAlexis Rovner, founder of 64-x, on genome design
- PartnerInaugural Advanced Therapy Incubator Cohort
- Company64x Bio Emerges from Stealth
- Company64x Bio Raises $55 Million Series A Financing
- Company64x Bio Launches AAV Apex Suite
- Company64x Bio Launches LV Apex Suite
- Company64x Bio website and YC profile
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
